This is the authors' abstract. We don't add key points for this paper.
Background and Objective To assess the efficacy of intravitreal aflibercept 8 mg in treating neovascular age-related macular degeneration (nAMD) in patients previously treated with faricimab. Patients and Methods A retrospective study was conducted on nAMD patients with suboptimal response to faricimab injections who were switched to intravitreal aflibercept 8 mg. Visual acuity (VA) and optical coherence tomography features were evaluated. Results The study included 135 eyes from 85 patients who received an average of 7.4 (4) faricimab injections with a mean interval of 53 days, which decreased to 48 days by the 5th aflibercept 8 mg injection ( P = 0.056). Mean VA at the time of switch was 63.9 (14.4) letters and was 65 (13.5) letters after four aflibercept 8 mg injections ( P = 0.726). Mean central foveal thickness (CFT) at switch was 325 (104) µm which decreased to 272 (65) after four aflibercept 8 mg injections ( P < 0.001). The incidence of intraretinal fluid and subretinal hemorrhage increased from 31.3% and 8.1% at switch to 52.2% and 21.7% ( P = 0.029 and 0.004), respectively. Conclusions Switching from faricimab to aflibercept 8 mg did not result in interval extension or VA improvement. CFT decreased, but intraretinal fluid and subretinal hemorrhage increased. Further studies are warranted. [ Ophthalmic Surg Lasers Imaging Retina 2025;56:206–211.]
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Momenaei et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: